CIBERESUCICOVID is a fundamental study to improve care of critical patients of COVID-19. Its results will definitely contribute to improve diagnosis and treatment, to decrease mortality, and improve the quality of life of survivors

Collaborate with us!
Those interested in participating in the investigation may directly contact the Study Coordinator, Adrián Ceccato, by clicking on the « join the study » button.

Dr. Antoni Torres, a pneumologist at Hospital Clínic, head of the group applied Research in Respiratory Infections and Critically Ill Patients, and group leader of the CIBER of Respiratory Diseases (CIBERES), explains about the study of risk factors and prognosis of patients admitted to ICUs.

Description of the Study:

  • Title: Personalized Risk and Prognosis Factors and Follow-up at One Year of the Patients Hospitalized in the Spanish Intensive Care Units Infected with COVID-19 (CIBERESUCICOVID).
  • Principal Investigator: Antoni Torres Martí.
  • Co-Investigators: Ferran Barbé Illa, Ricard Ferrer, Jesús Bermejo, Alejandro Rodríguez, Rosario Menéndez and et al.
  • Centers of Implementation: At more than 50 Spanish ICUs.
  • Study Population: 5000 patients.

Objectives of the Study:

Principal Objective: To determine, through artificial intelligence analysis, which are the risk and prognosis factors of patients infected with COVID-19 that are hospitalized in the Spanish ICUs since the pandemic started in Spain and until it is finished.

Secondary Objectives:
(1) To perform the follow-up of patients since their release from the ICU and from the hospital until one year later, to determine mortality at six months and at one year, and the repercussions in respiratory and cardiovascular function, as well as in the quality of life.
(2) To perform the epigenetic study of those cases in which a blood sample is obtained.
(3) To evaluate the impact over the prognosis of a panel of biomarkers in physiological routes which are key in the pathogenesis of the disease, with the goal of identifying the treatments which are more likely to be successful in each patient.

More about this Study:

Added Value: CIBERESUCICOVID is a study that brings together the main Spanish scientific societies related to respiratory diseases with critical COVID-19 patients.

Logo Ciberes 1
Instituto de Salud Carlos III finances this study to improve care of critical COVID-19 patients.

Other Studies about Pharmacology:

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la…

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

Vaccination In People With Long COVID

This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.

Antibiotic prescription during the COVID-19 pandemic

Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.

Antihistamines and azithromycin as a treatment for COVID-19

This study suggests that primary care diagnosis and treatment with antihistamines, plus azithromycin in selected cases, may treat COVID-19 and prevent progression to severe disease…

Immunomodulatory Treatment In Patients With Severe Pneumonia COVID-19

Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this…

Real-life Use Of Remdesivir In Hospitalized Patients With COVID-19

This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19.

Prevention With Calcifediol Of Respiratory Problems Caused By COVID-19

This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.

Maraviroc in patients hospitalized for COVID-19

Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2…